简体中文 | 繁體中文 | English

Health and Pharmaceutical Press Releases

2025-12-08 15:31 Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH
2025-12-08 14:51 Galderma Welcomes Increased Equity Investment From L’Oréal
2025-12-08 11:26 Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
2025-12-08 10:51 Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation
2025-12-05 16:53 Parse Biosciences Launches Evercode Whole Blood Fixation
2025-12-05 16:37 IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
2025-12-05 14:48 Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body
2025-12-05 10:41 University of Maryland Launches Innovative Clinician Training Program in Ketogenic Metabolic Therapy for Mental Health
2025-12-05 09:59 Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings
2025-11-27 10:05 U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
2025-11-26 15:12 With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?
2025-11-26 15:08 Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg
2025-11-26 14:52 NEL Animal Medical Foundation Becomes First in Korea to Achieve 100 Open-Heart Surgeries
2025-11-25 10:06 Merck Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis
2025-11-24 11:32 BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
2025-11-21 10:59 Synthio Labs Raises $5 Million to Build the Voice AI Operating System for Life Sciences Customer Engagement
2025-11-20 14:44 Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
2025-11-20 11:34 Parse Biosciences Announces FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis
2025-11-20 11:19 Sharjah Emerges as a Global Hub for Medical Innovation and Collaborative R&D
2025-11-19 10:56 Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

Business Wire Weibo

Press Releases

Latest Releases